The potential cost-savings of tumour necrosis factor inhibitors for hidradenitis suppurativa
Br J Dermatol
.
2019 May;180(5):988-989.
doi: 10.1111/bjd.17729.
Author
R G Micheletti
1
Affiliation
1
Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA, 19104-4211, U.S.A.
PMID:
31025755
DOI:
10.1111/bjd.17729
No abstract available
Publication types
Comment
MeSH terms
Adalimumab
Hidradenitis Suppurativa*
Humans
Retrospective Studies
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha
Substances
Tumor Necrosis Factor Inhibitors
Tumor Necrosis Factor-alpha
Adalimumab